The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 13.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 54% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 69%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (1 analysts) rates it none, with a mean price target of $10.
Pyxis Tankers Inc
PXS · NASDAQ · USD · Market cap $44M
Pyxis Tankers Inc.
FAIL · Does not pass the screenPrice as of 3 Nov 2026Daily close, not a live quote
Screened 2026-11-03 · the tape above runs as of 08:06 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price6.53 USD at the 3 Nov 2026 close
- Fair valueUnder review: only one analyst covers it, too few to cross-check it; our model's value is 1.54x the price, above our 1.35x limit.
- Our regime readDistribution, as of 3 Nov 2026
- Ethical screenDoes not pass
- Last reviewed3 Nov 2026 (1 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-11-03).
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Pyxis Tankers Inc holds its Distribution at $6.53. Consolidating, no directional conviction, held for 22 days.
| Phase | Distribution · caution |
| Quantitative state | Consolidating, no directional conviction, held for 22 days |
| Price at the screen | $6.53 |
| Valuation | 21.03 trailing · 5.04 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | -0.52 |
Five Screens, Shown in Full
Does not pass. Debt ratio
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 45.11% | Below 33% | Interest-bearing debt is 45.1% of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | 9.31% | Below 33% | Cash held in interest-bearing accounts and securities is 9.3% of assets, under the one-third limit. | Pass |
| Receivables | 19.42% | Below 49% | Money owed to the company is 19.4% of assets, under the 49% limit. | Pass |
| Revenue purity | 4.60% | Below 5% | Only 4.6% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Pyxis Tankers's business is in a permissible area, but its interest-bearing debt is about 45% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-04. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when PXS's ethical verdict changes
Today PXS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value under review. Only one analyst covers it, too few to cross-check it; our model's value is 1.54x the price, above our 1.35x limit. We show no fair value, margin of safety or value read built on it until the review clears.
How a fair value is estimated: discounted cash flow (DCF).
Price History & ProjectionsWhere our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-03 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| Forward P/E | 5.0xpriced for continued growth |
| Trailing P/E | 21.0xa premium valuation |
| EPS, trailing | 0.35 |
| EPS, forward | 1.46 |
| Revenue growth | +3.9%slow but positive growth |
| Profit margin | 9.3%thin but positive margins |
| Return on equity | 3.9%a modest return on shareholder capital |
| FCF yield | 23.80% |
| Debt to equity | 0.82moderate, manageable leverage |
| Current ratio | 4.53comfortably covers its short-term bills |
| Beta | -0.52barely tracks the market's swings |
| Short interest, float | 0.01% |
| 52-week range | 2.47 - 4.92 |
| Moat | NONE |
| Market cap | $44M |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to Greece and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradePXS trades on NASDAQ (the company is based in Greece). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 77% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 69%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (1 analysts) rates it none, with a mean price target of $10.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 69.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 39% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 69%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (1 analysts) rates it none, with a mean price target of $10.
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 39% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 69%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (1 analysts) rates it none, with a mean price target of $10.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 6.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 39% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 69%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (1 analysts) rates it none, with a mean price target of $10.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 39% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 69%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (1 analysts) rates it none, with a mean price target of $10.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $4.48 | +4.0% | · | $1,040 | +4.0% |
| 2 months | $4.45 | +4.7% | · | $1,047 | +4.7% |
| 3 months | $3.88 | +20.1% | · | $1,201 | +20.1% |
| 6 months | $3.02 | +54.6% | · | $1,546 | +54.6% |
| 1 year | $2.76 | +69.2% | · | $1,692 | +69.2% |
| 2 years | $5.18 | -10.0% | · | $900 | -10.0% |
| 3 years | $3.72 | +25.3% | · | $1,253 | +25.3% |
| 5 years | $3.71 | +25.7% | · | $1,257 | +25.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever PXS does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.